Glioblastoma (GBM) is the most prevalent primary brain tumor and ranks among the most
lethal of human cancers with conventional therapy offering only palliation. Great strides have
been made in understanding brain cancer genetics and modeling these tumors with new
targeted therapies being tested, but these advances have not translated into substantially
improved patient outcomes. Multiple chemotherapeutic agents, including temozolomide, the
first-line treatment for glioblastoma, have been developed to kill cancer cells. However, the …